GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » EBITDA Margin %

Cosmo Pharmaceuticals NV (CHIX:COPNZ) EBITDA Margin % : 34.63% (As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cosmo Pharmaceuticals NV's EBITDA for the six months ended in Jun. 2023 was CHF14.7 Mil. Cosmo Pharmaceuticals NV's Revenue for the six months ended in Jun. 2023 was CHF42.6 Mil. Therefore, Cosmo Pharmaceuticals NV's EBITDA margin for the quarter that ended in Jun. 2023 was 34.63%.


Cosmo Pharmaceuticals NV EBITDA Margin % Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV EBITDA Margin % Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.79 -11.24 12.86 62.03 46.52

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.28 101.37 49.33 44.59 34.63

Competitive Comparison of Cosmo Pharmaceuticals NV's EBITDA Margin %

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo Pharmaceuticals NV's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's EBITDA Margin % falls into.



Cosmo Pharmaceuticals NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cosmo Pharmaceuticals NV's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=46.864/100.748
=46.52 %

Cosmo Pharmaceuticals NV's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=14.749/42.592
=34.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosmo Pharmaceuticals NV  (CHIX:COPNz) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Cosmo Pharmaceuticals NV EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Headlines

No Headlines